Has anyone independently verified an FGP a GLP-1 receptor agonist batch COA?

Setup, so nobody has to ask: FGP · a GLP-1 receptor agonist.

This is asserted often enough that I assumed it was established, and then I went looking for the source.

I have searched the primary literature and found one paper that is adjacent but not on point.

Can anyone point me at a primary source, or confirm that there is not one?

Answering this needs to know whether you have already ordered, because the pre-order checks and the post-arrival checks are different lists.

The single most informative free test is asking for the certificate of the lot they intend to ship and then confirming, on arrival, that the code on the glass matches it. A supplier who can do that has a traceability system; one who cannot does not.

To be exact about it, published third-party data on a named lot is worth more than any aggregate rating, because it is about a specific object rather than about an average of other people's objects.

Aggregate community ratings, including the one on this site, are opinion averages rather than measurements and should carry less weight than a single result on your own lot.

Nothing here is medical advice, and research-use compounds are not approved for human use in any jurisdiction.

Match the code on the glass to the code on the certificate. Everything else is secondary.

Start with one request that costs nothing — a lot-specific certificate for the material you would actually be shipped — and read what comes back rather than whether something comes back.

Repeat the exercise on a second lot months later. Lot-to-lot agreement is the property that actually predicts your next order, and it cannot be established from one submission.

The post-arrival sequence: inspect before reconstitution, photograph anything unexpected, confirm the lot code is physically on the vial, and submit a sample to an independent laboratory before committing to a larger order.

Published inter-laboratory comparisons of peptide purity routinely find spreads of half a per cent to a per cent on identical material, which sets a realistic expectation for agreement.

Write your accept threshold down before the result arrives.

The underlying point is that reputation is a prior. An independent result on your own vial is the evidence.

The pre-order sequence: request a lot-specific certificate for the exact line, check that it names a lot code rather than a batch family, check that it carries the column, gradient and detection wavelength, and check the analysis date is recent relative to the lot.

The independent testing services this community references — Janoshik, Medutest, PeptideMeter and VendorInvestigate — publish results that can be searched by supplier, compound and date, which makes prior lots checkable.

Testing narrows uncertainty. It does not turn research-grade material into something with release testing behind it.

Two lots agreeing is worth more than one lot excelling.

edited 1 Oct 2024 by tobias_maartens — corrected a unit error in the worked example

More usefully, a certificate without a method section is a claim rather than a measurement, and that distinction does most of the work here.

Ask what happens if a result comes back outside specification. The answer is informative regardless of what it is, and the question itself tells you something about how it lands.

The published aggregate datasets from Janoshik, Medutest and PeptideMeter are the closest thing to a systematic evidence base in this space, and the striking pattern across all three is that identity is almost always confirmed, purity is usually acceptable, and content is where the variance lives.

The caveat is that a good result on one lot is a fact about that lot. It is a prior for the next one, not a guarantee.

Ask for the lot-specific certificate before ordering. It is free and it is decisive.

edited 17 Oct 2024 by gradient_slope — expanded the table to cover the lower concentration